Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

279
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
279
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reticulocyte Hemoglobin Content (CHr): The Gold Standard for Diagnosing Iron Deficiency.

The Journal of the Association of Physicians of India·2019
Same author

A Novel G6PD p. Gly 321 Val Mutation Causing Severe Hemolysis in an Indian Infant.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2019
Same author

Is cancer chemotherapy dying?

Asian journal of transfusion science·2016
Same author

Telomeres and diseases.

The Journal of the Association of Physicians of India·2015
Same author

Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2015
Same author

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology·2015
Same journal

Influencing Factor Analysis and Predictive Model Development for Platelet Transfusion Refractoriness in Pediatric Oncology Patients.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same journal

Reducing On-Shelf Wastage of Fresh Frozen Plasma and Cryoprecipitate in a Tertiary Care Hospital Blood Centre: A Clinical Audit Using the Plan-Do-Study-Act (PDSA) Method.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same journal

Real Egyptian Single-Center Experience in Mantle Cell Lymphoma Diagnosis and Management.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same journal

The Effect of Diabetes mellitus Type2 on Mobilization and Autologous Hematopoietic Stem Cell Transplantation Outcomes.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same journal

Outcome of Low Dose Azacitidine in Patients of Lower Risk Myelodysplastic Syndromes.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same journal

Outcome of Low Dose Azacitidine in Patients of Lower Risk Myelodysplastic Syndromes.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Multiple Myeloma: Treatment is Getting Individualized.

M B Agarwal1

  • 1Department of Haematology, Bombay Hospital Institute of Medical Sciences, Mumbai, India.

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
|February 9, 2016
PubMed
Summary
This summary is machine-generated.

Novel therapies like immunomodulatory drugs and proteasome inhibitors are transforming multiple myeloma (MM) treatment. Advances in risk stratification and minimal residual disease detection enable personalized, risk-based therapy for better patient outcomes.

Keywords:
MyelomaNovelPersonalizedRiskStratificationTreatment

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Related Experiment Videos

Last Updated: Mar 26, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Multiple myeloma (MM) is a complex blood cancer with variable patient outcomes.
  • Conventional chemotherapy is being replaced by novel therapeutic agents.
  • Emerging treatments like monoclonal antibodies promise further improvements.

Purpose of the Study:

  • To review the advancements in multiple myeloma treatment and risk stratification.
  • To highlight the role of novel agents and diagnostic techniques in managing MM.
  • To discuss the impact of understanding MM biology on therapeutic strategies.

Main Methods:

  • Review of current literature on multiple myeloma therapies and diagnostics.
  • Analysis of novel drug classes including immunomodulatory drugs and proteasome inhibitors.
  • Discussion of risk stratification systems and minimal residual disease detection methods.

Main Results:

  • Novel agents have significantly improved response rates in MM.
  • Risk stratification systems allow for better prediction of disease course.
  • Minimal residual disease detection aids in treatment modification.
  • Understanding of MM cell-environment interactions and genetic factors reveals new therapeutic targets.

Conclusions:

  • Current therapeutic strategies focus on risk-based, individualized treatment for multiple myeloma.
  • Ongoing research into MM biology is paving the way for novel treatment approaches.
  • The future of MM management involves personalized medicine driven by advanced diagnostics and targeted therapies.